<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[6, 9] specific airway resistance<br>[123, 129] Spirographic and sRAW-based criteria<br>[139, 140] sRAW<br>[144, 147] intrathoracic gas volume<br>[156, 158] residual volume<br>[167, 168] FVC<br>[183, 184] FEV1<br>[187, 188] FVC<br>[199, 200] ITGV<br>[204, 205] RV<br>[210, 211] VAS<br></td>
<td width=33%>
[2, 5] acute bronchodilator effects<br>[6, 10] specific airway resistance changes<br>[29, 32] forced expiratory volume<br>[123, 129] Spirographic and sRAW-based criteria<br>[139, 140] sRAW<br>[144, 147] intrathoracic gas volume<br>[156, 161] residual volume (RV)<br>[167, 168] FVC<br>[175, 176] VAS<br>[183, 184] FEV1<br>[187, 188] FVC<br>[199, 200] ITGV<br>[204, 205] RV<br>[210, 211] VAS<br>[222, 223] sRAW.<br>[229, 236] functional effect of bronchodilators, sRAW-<br>[241, 243] FEV1-FVC-<br>[251, 255] bronchodilator-induced improvements<br></td>
<td width=33%>
[0, 10] Assessment of acute bronchodilator effects from specific airway resistance changes<br>[29, 33] forced expiratory volume at<br>[34, 45] (FEV1) and forced vital capacity (FVC).<br>[55, 68] decrease dynamic hyperinflation, gas trapping, and possibly dyspnea at rest.<br>[73, 80] specific airway resistance changes (sRAW)<br>[84, 89] acute response to bronchodilators.<br>[99, 109] dyspnea evaluation (VAS score) and pulmonary function testing<br>[123, 129] Spirographic and sRAW-based criteria<br>[139, 140] sRAW<br>[144, 150] intrathoracic gas volume (ITGV)<br>[156, 161] residual volume (RV)<br>[167, 168] FVC<br>[175, 176] VAS<br>[183, 184] FEV1<br>[187, 188] FVC<br>[199, 201] ITGV (<br>[202, 211] ), RV (p=0.023), and VAS<br>[222, 223] sRAW.<br>[228, 238] acute functional effect of bronchodilators, sRAW-based criterion<br>[241, 246] FEV1-FVC-based criteria,<br>[251, 260] bronchodilator-induced improvements of lung mechanics and dyspnea<br></td>
</tr>
